ResMed Inc. 10-Q Filing Summary
Business Context and Reporting Period
Company: ResMed Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2004 (Six months ended December 31, 2004)
Business Overview: ResMed designs, manufactures, and markets medical devices for the evaluation and treatment of sleep-disordered breathing, primarily obstructive sleep apnea. Operations include manufacturing in Australia, Germany, and the U.S., with major distribution sites globally.
Key Financial Metrics
| Metric (in thousands, except per share) | Six Months Ended Dec 31, 2004 | Six Months Ended Dec 31, 2003 |
|---|---|---|
| Net Revenue | $191,626 | $155,170 |
| Gross Profit | $124,789 | $99,582 |
| Gross Margin | 65.1% | 64.2% |
| Operating Income | $46,569 | $38,347 |
| Net Income | $31,330 | $26,400 |
| Diluted EPS | $0.89 | $0.75 |
| Cash from Operations | $38,930 | $25,997 |
| Cash & Equivalents (Ending) | $143,068 | $107,462 |
| Total Debt (Convertible Notes) | $113,250 | $113,250 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 23% year-over-year, driven by a 26% increase in unit sales of flow generators and masks. Currency appreciation contributed approximately $6.8 million to the six-month revenue increase.
- Profitability: Gross profit increased 25%, with margins improving to 65% from 64% due to a favorable product mix (higher margin masks), partially offset by higher Australian manufacturing costs due to currency strength.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 25% to $60.1 million, primarily due to increased personnel and currency effects. R&D expenses increased 15% to $14.7 million.
- Restructuring: The company incurred $2.9 million in restructuring expenses related to the integration of ResMed Germany and MAP operations.
- Acquisitions: Acquired Resprecare BV (Dutch distributor) for $5.8 million in cash on December 1, 2004, recording $5.3 million in goodwill.
Guidance, Outlook, and Risks
- Outlook: Management expects to complete the new sleep center in the first half of calendar 2005 and R&D/office facilities in the second half of 2006. Estimated additional building costs are approximately $52 million.
- Liquidity: The company maintains strong liquidity with $165 million in cash and marketable securities. A $15 million undrawn revolving line of credit is available.
- Capital Allocation: Continued share repurchases under a $4 million authorization; 241,090 shares repurchased in the six-month period for $11.0 million.
- Risks:
- Currency: Significant exposure to Australian dollar and Euro fluctuations affecting both revenue and manufacturing costs.
- Regulatory: Dependence on FDA and international regulatory approvals; potential for reimbursement reductions by government and private payers.
- Integration: Risks associated with integrating acquired entities (e.g., Resprecare, German operations).
- Tax: Ongoing tax audit in Germany for years 1996-1998; outcome uncertain.
Investor Verification Checklist
- Verify the impact of the Australian dollar strength on future gross margins given the concentration of manufacturing costs in Australia.
- Monitor the completion and cost overruns of the Norwest Business Park campus expansion ($52 million estimated).
- Review the final allocation of the Resprecare BV purchase price, specifically the reclassification of goodwill to identifiable intangibles.
- Assess the outcome of the German tax audit and potential liability for years 1996-1998.
- Track the execution of the German operations integration and associated restructuring cost savings.